EXHIBIT 4.2
THIS WARRANT AND THE SECURITIES ISSUABLE UPON
EXERCISE OR REDEMPTION HEREOF HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR ANY STATE SECURITIES LAW, AND MAY NOT BE SOLD,
TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED
OF OR EXERCISED UNLESS (I) A REGISTRATION STATEMENT
REGISTERING SUCH SECURITIES UNDER THE SECURITIES ACT AND APPLICABLE
STATE SECURITIES LAWS SHALL HAVE BECOME EFFECTIVE, OR (II) THE
COMPANY HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO IT THAT
SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER
THE SECURITIES ACT OR QUALIFICATION UNDER APPLICABLE STATE
SECURITIES LAWS, OR (III) SUCH SECURITIES ARE SOLD PURSUANT TO
RULE 144 OR RULE 144A.
AN INVESTMENT IN THESE SECURITIES INVOLVES A
HIGH DEGREE OF RISK. HOLDERS MUST RELY ON THEIR OWN ANALYSIS OF THE
INVESTMENT AND ASSESSMENT OF THE RISKS INVOLVED.
|
|
|
|
|
Warrant to Purchase
|
|
|
|
Shares
|
|
Warrant
Number
|
|
|
|
|
Warrant to Purchase Common
Stock
of
ARRAY BIOPHARMA
INC.
THIS CERTIFIES that
or any subsequent holder hereof (“ Holder ”) has
the right to purchase from ARRAY BIOPHARMA INC., a Delaware
corporation, (the “ Company ”),
( )
fully paid and nonassessable shares, of the Company’s common
stock, $0.001 par value per share (“ Common Stock
”), subject to adjustment as provided herein, at a price
equal to the Exercise Price (as defined in Section 3 below),
at any time during the Term (as defined below).
Holder agrees with the Company that this Warrant
to Purchase Common Stock of the Company (this “
Warrant ” or this “ Agreement ”) is
issued and all rights hereunder shall be held subject to all of the
conditions, limitations and provisions set forth herein.
1. Date of Issuance and Term.
This Warrant shall be deemed to be issued on
[ ], 2009 (“
Date of Issuance ”). The term of this Warrant begins
on the Date of Issuance and ends at 5:00 p.m., New York City
time on April 29, 2014 (the “ Term ”). This
Warrant was issued in conjunction with that certain Facility
Agreement (the “ Facility Agreement ”) by and
between the Company and Deerfield Private Design Fund, L.P., a
Delaware limited partnership, and Deerfield Private Design
International, L.P., a limited partnership organized under the laws
of the British Virgin Islands (individually, a “
Lender ” and together, the “ Lenders
”), that certain Registration Rights Agreement (“
Registration Rights Agreement ”) by and between the
Company and the Lenders, each dated May 15, 2009, entered into
in conjunction herewith.
Notwithstanding anything herein to the contrary,
the Company shall not issue to the Holder, and the Holder may not
acquire, a number of shares of Common Stock upon exercise of this
Warrant to the extent that, upon such exercise, the number of
shares of Common Stock then beneficially owned by the
Holder
[***] Certain confidential information contained
in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to
Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
and its Affiliates and any other persons or
entities whose beneficial ownership of Common Stock would be
aggregated with the Holder’s for purposes of
Section 13(d) of the Securities Exchange Act of 1934 (the
“ Exchange Act ”) (including shares held by any
“group” of which the Holder is a member, but excluding
shares beneficially owned by virtue of the ownership of securities
or rights to acquire securities that have limitations on the right
to convert, exercise or purchase similar to the limitation set
forth herein) would exceed 9.98% of the total number of shares of
Common Stock then issued and outstanding (the “ 9.98%
Cap ”), provided, however, that the 9.98% Cap shall not
apply with respect to the issuance of shares of Common Stock
pursuant to a Redemption Upon Major Transaction (as defined below)
in connection with a Major Transaction (as defined below) covered
by the provisions of Section 5(c)(i)(A)(1) below in which
the Company is not the surviving entity (a “ Qualified
Change of Control Transaction ”) to the extent that the
number of shares beneficially owned by the Holder and its
affiliates in the successor entity immediately following
consummation of such Qualified Change of Control Transaction does
not exceed 9.98% of the outstanding common stock of such successor
entity and provided, further, that the 9.98% Cap shall only apply
to the extent that the Common Stock is deemed to constitute an
“equity security” pursuant to Rule 13d-1(i) promulgated
under the Exchange Act. For purposes hereof,
“group” has the meaning set forth in Section 13(d)
of the Exchange Act and applicable regulations of the Securities
and Exchange Commission (the “ SEC ”), and the
percentage held by the Holder shall be determined in a manner
consistent with the provisions of Section 13(d) of the
Exchange Act. Upon the written request of the Holder, the Company
shall, within two (2) Trading Days confirm orally and in
writing to the Holder the number of shares of Common Stock then
outstanding.
“ Affiliate ” means any
person or entity that, directly or indirectly through one or more
intermediaries, controls or is controlled by or is under common
control with a person or entity, as such terms are used in and
construed under Rule 144 under the Securities Act of 1933, as
amended (the “ Securities Act ”). With respect
to a Holder of Warrants, any investment fund or managed account
that is managed on a discretionary basis by the same investment
manager as such Holder will be deemed to be an Affiliate of such
Holder.
“ Business Day ” means
a day on which banks are open for business in The City of New
York.
“ Holder ” means Deerfield
Private Design International, L.P. and any transferee or assignee
pursuant to the terms of this Warrant.
“ Trading Day ” means any day
on which the Common Sock is traded for at least two hours on
NASDAQ, or on the principal securities exchange or other securities
market on which the Common Stock is then being traded.
2. Exercise .
(a) Manner of Exercise.
During the period beginning on the
earlier of (x) the six-month anniversary of the date a
“Disbursement” is made pursuant to Section 2.2 of
the Facility Agreement and (y) September 9, 2009 if a
“Disbursement Request” shall not have been received
pursuant to the terms of the Facility Agreement between the date
hereof and the close of business on September 9, 2009, and
ending at 5:00 p.m., New York City time on April 29,
2014, this Warrant may be Exercised as to all or any lesser number
of full shares of Common Stock covered hereby (the “
Warrant Shares ” or the “ Shares ”)
upon surrender of this Warrant, with the Exercise
Form attached hereto as Exhibit A (the “
Exercise Form ”) duly completed and executed, together
with the full Exercise Price (as defined below, which may be
satisfied by a Cash Exercise or a Cashless Exercise, as each is
defined below) for each share of Common Stock as to which this
Warrant is Exercised, at the office of the Company, Array BioPharma
Inc., 3200 Walnut Street, Boulder, CO 80301; Attention: Chief
Financial Officer Phone: (303) 381-6663, Fax: (303) 381-6697, or at
such other office or agency as the Company may designate in
writing, by overnight mail,
[***] Certain confidential information contained
in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to
Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
2
with an advance copy of the Exercise
Form sent to the Company and its transfer agent (“
Transfer Agent ”) by facsimile (such surrender and
payment of the Exercise Price hereinafter called the “
Exercise ” of this Warrant).
(b) Date of Exercise.
The “ Date of Exercise
” of the Warrant shall be defined as the date that the
Exercise Form attached hereto as Exhibit A ,
completed and executed, and the original Warrant are received by
the Company and the Exercise Price is satisfied pursuant to
Section 3 below. Upon receipt of the properly completed
and executed Exercise Form, the original Warrant and the Exercise
Price by the Company, the Holder shall be deemed for all corporate
purposes to have become the holder of record of the Warrant Shares
with respect to which this Warrant has been Exercised, irrespective
of the date such Warrant Shares are credited to the Holder’s
Depository Trust Company (“ DTC ”) account or
the date of delivery of the certificates evidencing such Warrant
Shares as the case may be.
(c) Delivery of Common Stock Upon
Exercise. Within three
(3) Business Days after any Date of Exercise (the “
Delivery Period ”), the Company shall issue and
deliver (or cause its Transfer Agent so to issue and deliver) in
accordance with the terms hereof to or upon the order of the Holder
that number of shares of Common Stock (“ Exercise
Shares ”) for the portion of this Warrant Exercised as
shall be determined in accordance herewith. Upon the Exercise of
this Warrant or any part thereof, the Company shall, at its own
cost and expense, take all reasonable steps, including obtaining
and delivering an opinion of counsel, to assure that the Transfer
Agent shall issue stock certificates in the name of Holder (or its
nominee) or such other persons as designated by Holder and in such
denominations to be specified at Exercise representing the number
of shares of Common Stock issuable upon such Exercise. The Company
warrants that no instructions contrary to these instructions have
been or will be given to the Transfer Agent and that, unless waived
by the Holder, the Exercise Shares will be free-trading, and freely
transferable, and will not contain a legend restricting the resale
or transferability of the Exercise Shares if the Unrestricted
Conditions (as defined in paragraph 2(e)(ii) below) are
met.
(d) Delivery Failure.
In addition to any other remedies
which may be available to the Holder, in the event that the Company
fails for any reason to effect delivery of the Exercise Shares by
the end of the Delivery Period (a “ Delivery Failure
”), the Holder will be entitled to revoke all or part of the
relevant Exercise Form by delivery of a notice to such effect
to the Company whereupon the Company and the Holder shall each be
restored to their respective positions immediately prior to the
delivery of such notice, except that the liquidated damages
described herein shall be payable through the date notice of
revocation or rescission is given to the Company.
(e) Legends.
(i) Restrictive Legend
. The Holder understands that until such time as this Warrant, the
Exercise Shares and the Redemption Shares have been registered
under the Securities Act as contemplated by the Registration Rights
Agreement or otherwise may be sold pursuant to Rule 144 under
the Securities Act or an exemption from registration under the
Securities Act without any restriction as to the number of
securities as of a particular date that can then be immediately
sold, this Warrant, the Exercise Shares and the Redemption Shares,
as applicable, shall bear a restrictive legend in substantially the
following form (and a stop-transfer order may be placed against
transfer of the certificates for such securities):
“THE SECURITIES REPRESENTED BY
THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY
STATE SECURITIES LAW, AND MAY NOT BE SOLD, TRANSFERRED,
ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF OR
EXERCISED UNLESS (I) A REGISTRATION STATEMENT REGISTERING SUCH
SECURITIES UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES
LAWS SHALL HAVE BECOME EFFECTIVE, OR
[***] Certain confidential information contained
in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to
Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
3
(II) THE COMPANY HAS RECEIVED
AN OPINION OF COUNSEL SATISFACTORY TO IT THAT SUCH TRANSFER
MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES
ACT OR QUALIFICATION UNDER APPLICABLE STATE SECURITIES LAWS, OR
(III) SUCH SECURITIES ARE SOLD PURSUANT TO RULE 144 OR RULE
144A.”
“THE SALE, TRANSFER OR
ASSIGNMENT OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE
SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN REGISTRATION
RIGHTS AGREEMENT DATED AS OF MAY 15, 2009, AS AMENDED FROM
TIME TO TIME, AMONG THE COMPANY AND CERTAIN HOLDERS OF ITS
OUTSTANDING SECURITIES. COPIES OF SUCH AGREEMENT MAY BE
OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD
OF THIS CERTIFICATE TO THE SECRETARY OF THE
COMPANY.”
(ii) Removal of Restrictive
Legends . This Warrant, the certificates evidencing the
Exercise Shares and any Redemption Shares, as applicable, shall not
contain any legend restricting the transfer thereof (including the
legend set forth above in subsection 2(e)(i)): (A) while a
registration statement (including a Registration Statement, as
defined in the Registration Rights Agreement, or any Shelf
Registration Statement with respect to Redemption Shares, as
defined in Section 4(c) below) covering the resale of
such security is effective under the Securities Act, or
(B) following any sale of such Warrant, Exercise Shares and/or
Redemption Shares pursuant to Rule 144, or (C) if such
Warrant, Exercise Shares and/or Redemption Shares are eligible for
sale under Rule 144(b)(1)(i), or (D) if such legend is
not required under applicable requirements of the Securities Act
(including judicial interpretations and pronouncements issued by
the staff of the SEC) and the Company shall have received an
opinion of counsel of Holder to such effect (collectively, the
“ Unrestricted Conditions ”). The Company
shall cause its counsel to issue a legal opinion to the Transfer
Agent promptly after the Effective Date (as defined below) if
required by the Company’s transfer agent to effect the
issuance of the Exercise Shares or any Redemption Shares without a
restrictive legend or removal of the legend hereunder. If the
Unrestricted Conditions are met at the time of issuance of this
Warrant, Exercise Shares and/or Redemption Shares, then such
Warrant, Exercise Shares and/or Redemption Shares shall be issued
free of all legends. The Company agrees that following the
Effective Date or at such time as the Unrestricted Conditions are
met or such legend is otherwise no longer required under this
Section 2(e), it will, no later than three (3) Trading
Days following the delivery (the “ Unlegended Shares
Delivery Deadline ”) by the Holder to the Company or the
Transfer Agent of this Warrant and a certificate representing
Exercise Shares or Redemption Shares, as applicable, issued with a
restrictive legend (such third Trading Day, the “ Legend
Removal Date ”), deliver or cause to be delivered to such
Holder this Warrant and/or a certificate (or electronic transfer)
representing such shares that is free from all restrictive and
other legends. For purposes hereof, “ Effective Date
” shall mean the date that the Registration Statement that
the Company is required to file pursuant to the Registration Rights
Agreement or any Shelf Registration Statement pursuant to
Section 4(c) below has been declared effective by the
SEC.
(iii) Sale of Unlegended
Shares . Holder agrees that the removal of the restrictive
legend from this Warrant and any certificates representing
securities as set forth in this Section 2(e)(ii) above is
predicated upon the Company’s reliance that the Holder will
sell this Warrant, Exercise Shares and/or Redemption Shares
pursuant to either the registration requirements of the Securities
Act, including any applicable prospectus delivery requirements, or
an exemption therefrom, and that if such securities are sold
pursuant to a Registration Statement, they will be sold in
compliance with the plan of distribution set forth
therein.
(f) Cancellation of Warrant.
This Warrant shall be canceled upon
the full Exercise of this Warrant or upon full redemption of this
Warrant. As soon as practical after the Date of Exercise, Holder
shall be entitled to receive Common Stock for the number of shares
purchased upon Exercise of this Warrant, and if this Warrant is not
Exercised in full, Holder shall be entitled to receive a new
Warrant (containing
[***] Certain confidential information contained
in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to
Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
4
terms identical to this Warrant) representing
any unexercised portion of this Warrant in addition to such Common
Stock.
(g) Holder of Record.
Each person in whose name any
Warrant for shares of Common Stock is issued shall, for all
purposes, be deemed to be the Holder of record of such shares on
the Date of Exercise of this Warrant, irrespective of the date of
delivery of the Common Stock purchased upon the Exercise of this
Warrant. Nothing in this Warrant shall be construed as conferring
upon Holder any rights as a stockholder of the Company.
(h) Delivery of Electronic
Shares. In lieu of
delivering physical certificates representing the Common Stock
issuable upon Exercise or legend removal or representing Redemption
Shares, provided the Company’s Transfer Agent is
participating in the DTC Fast Automated Securities Transfer
(“ FAST ”) program, upon written request of the
Holder, the Company shall use commercially reasonable efforts to
cause its Transfer Agent to electronically transmit the Common
Stock issuable to the Holder by crediting the account of the
Holder’s prime broker with DTC through its Deposit Withdrawal
Agent Commission (DWAC) system. The time periods for delivery and
penalties described herein shall apply to the electronic
transmittals described herein. Any delivery not effected by
electronic transmission shall be effected by delivery of physical
certificates.
(i) Buy-In. In addition to any other rights available to the
Holder, if the Company fails to cause its Transfer Agent to
transmit to the Holder a certificate or certificates representing
the Exercise Shares pursuant to an Exercise on or before the
Delivery Period (other than a failure caused by any incorrect or
incomplete information provided by Holder to the Company hereunder
or the negligence or any act or failure to act of the Transfer
Agent), and if after such date the Holder is required by its broker
to purchase (in an open market transaction or otherwise) or the
Holder’s brokerage firm otherwise purchases shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the
Exercise Shares which the Holder anticipated receiving upon such
Exercise (a “ Buy-In ”), then the Company shall
(1) pay in cash to the Holder the amount by which (x) the
Holder’s total purchase price (including brokerage
commissions, if any) for the shares of Common Stock so purchased
exceeds (y) the amount obtained by multiplying (A) the
number of Exercise Shares that the Company was required to deliver
to the Holder in connection with the Exercise at issue times and
(B) the price at which the sell order giving rise to such
purchase obligation was executed, and (2) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent
number of Exercise Shares for which such Exercise was not honored
or deliver to the Holder certificate(s) representing the
number of shares of Common Stock that would have been issued had
the Company timely complied with its Exercise and delivery
obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In
with respect to an attempted Exercise to cover the sale of Common
Stock with an aggregate sale price giving rise to such purchase
obligation of $10,000, under subsection (1) of the immediately
preceding sentence, the Company shall be required to pay the Holder
$1,000. The Holder shall provide the Company written notice
indicating the amounts payable to the Holder in respect of the
Buy-In, together with applicable confirmations and other evidence
reasonably requested by the Company. Nothing herein shall limit a
Holder’s right to pursue any other remedies available to it
hereunder, at law or in equity including, without limitation, a
decree of specific performance and/or injunctive relief with
respect to the Company’s failure to timely deliver
certificates representing shares of Common Stock upon Exercise of
the Warrant as required pursuant to the terms hereof.
3. Payment of Warrant Exercise Price
.
(a) Exercise Price. The Exercise Price (“ Exercise
Price ”) shall initially equal
$[ ] per share subject to
adjustment pursuant to the terms hereof, including but not limited
to Section 5 below.
Payment of the Exercise Price may be made by
either of the following, or a combination thereof, at
the
[***] Certain confidential information contained
in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to
Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
5
election of Holder:
(i) Cash Exercise : The
Holder may exercise this Warrant in cash, bank or cashier’s
check or wire transfer (a “ Cash Exercise ”);
or
(ii) Cashless Exercise
: The Holder, at its option, may exercise this Warrant in a
cashless exercise transaction. In order to effect a Cashless
Exercise, the Holder shall surrender this Warrant at the principal
office of the Company together with notice of cashless election, in
which event the Company shall issue Holder a number of shares of
Common Stock computed using the following formula (a “
Cashless Exercise ”):
X = Y (A-B)/A
where: X = the number of
shares of Common Stock to be issued to Holder.
Y = the number of shares of Common
Stock for which this Warrant is being Exercised.
A = the Market Price of one
(1) share of Common Stock (for purposes of this
Section 3(a)(ii), where “ Market Price ,”
as of any date, means the average Volume Weighted Average Price (as
defined below) of the Company’s Common Stock over the five
(5) consecutive Trading Day period immediately preceding the
date in question.
B = the Exercise Price.
As used herein, the “
Volume Weighted Average Price ” for any security as of
any date means the volume weighted average sale price on The NASDAQ
Global Market (“ NASDAQ ”) as reported by, or
based upon data reported by, Bloomberg Financial Markets or an
equivalent, reliable reporting service mutually acceptable to and
hereafter designated by holders of a majority in interest of the
Warrants and the Company (“ Bloomberg ”) or, if
NASDAQ is not the principal trading market for such security, the
volume weighted average sale price of such security on the
principal securities exchange or trading market where such security
is listed or traded as reported by Bloomberg, or, if no volume
weighted average sale price is reported for such security, then the
last closing trade price of such security as reported by Bloomberg,
or, if no last closing trade price is reported for such security by
Bloomberg, the average of the bid prices of any market makers for
such security that are listed in the over the counter market by the
Financial Industry Regulatory Authority, Inc. or in the
“pink sheets” by the National Quotation
Bureau, Inc. If the Volume Weighted Average Price cannot be
calculated for such security on such date in the manner provided
above, the volume weighted average price shall be the fair market
value as mutually determined by the Company and the Holders of a
majority in interest of the Warrants being Exercised for which the
calculation of the volume weighted average price is required in
order to determine the Exercise Price of such Warrants.
For purposes of Rule 144 and sub-section
(d)(3)(ii) thereof, it is intended, understood and
acknowledged that the Common Stock issuable upon Exercise of this
Warrant in a Cashless Exercise shall be deemed to have been
acquired at the time this Warrant was issued. Moreover, it is
intended, understood and acknowledged that the holding period for
the Common Stock issuable upon Exercise of this Warrant in a
Cashless Exercise shall be deemed to have commenced on the date
this Warrant was issued.
(b) Dispute Resolution.
In the case of a dispute as to the
determination of the closing price or the Volume Weighted Average
Price of the Company’s Common Stock or the arithmetic
calculation of the Exercise Price, Market Price or any Redemption
Price, the Company shall submit the disputed determinations or
arithmetic calculations via facsimile within two (2) Business
Days of receipt, or deemed receipt, of the Exercise Notice or
Redemption Notice, or other event giving rise to such dispute, as
the case may be, to the Holder. If the Holder and the Company are
unable to agree upon such determination or calculation within two
(2) Business Days of such disputed determination or arithmetic
calculation being submitted to the Holder, then the Company shall,
within two (2) Business Days submit via facsimile (i) the
disputed
[***] Certain confidential information contained
in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to
Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
6
determination of the closing price or the Volume
Weighted Average Price of the Company’s Common Stock to an
independent, reputable investment bank selected by the Company and
approved by the Holder, which approval shall not be unreasonably
withheld or (ii) the disputed arithmetic calculation of the
Exercise Price, Market Price or any Major Transaction Warrant
Redemption Price to the Company’s independent, outside
accountant. The Company shall use commercially reasonable
efforts to cause the investment bank or the accountant, as the case
may be, to perform the determinations or calculations and notify
the Company and the Holder of the results no later than five
(5) Business Days from the time it receives the disputed
determinations or calculations. Such investment bank’s or
accountant’s determination or calculation, as the case may
be, shall be binding upon all parties absent demonstrable error,
and the Company and the Holder shall each pay one-half of the fees
and costs of such investment bank or accountant.
4. Transfer and Registration .
(a) Transfer Rights.
Subject to the provisions of
Section 8 of this Warrant, this Warrant may be transferred on
the books of the Company, in whole or in part, in person or by
attorney, upon surrender of this Warrant properly completed and
endorsed. This Warrant shall be canceled upon such surrender and,
as soon as practicable thereafter, the person to whom such transfer
is made shall be entitled to receive a new Warrant or Warrants as
to the portion of this Warrant transferred, and Holder shall be
entitled to receive a new Warrant as to the portion hereof
retained.
(b) Registrable Securities.
The Common Stock issuable upon the
Exercise of this Warrant has registration rights pursuant to the
Registration Rights Agreement.
(c) Registration of Redemption
Shares. The
Company agrees to prepare and file with the SEC one or more
“shelf” registration statement(s) on Form S-3
(the “ Shelf Registration Statement ”) for an
offering to be made on a continuous basis pursuant to Rule 415
of the Securities Act promptly following issuance of this Warrant,
and to use its commercially reasonable efforts to cause any such
Shelf Registration Statement to become effective as soon as
possible after such filing, covering the issuance of a sufficient
number of shares of Common Stock that may be deliverable by it upon
a redemption of this Warrant under Sections 5(c)(iii) or 11 or
in satisfaction of any Failure Payments (as defined in
Section 10 below) under Section 10. For so long as all or
any portion of this Warrant is outstanding, the Company agrees to
use its commercially reasonable efforts to ensure that any Shelf
Registration Statement shall continuously be effective and contain
a sufficient number of shares of Common Stock available to be
issued pursuant to any such Shelf Registration Statement to cover
shares estimated by the Company in good faith that may be issuable
by it upon a redemption of this Warrant under Sections
5(c)(iii) or 11 or in satisfaction of any Failure Payments
under Section 10, including by preparing and filing such
amendments (including post-effective amendments) and supplements to
any such Shelf Registration Statement and preparing and filing a
subsequent Shelf Registration Statement if a previously filed and
effective Shelf Registration Statement will no longer deemed
current and effective or such Shelf Registration Statement does not
cover a sufficient number of shares that may be issuable by the
Company upon a redemption of this Warrant under Sections
5(c)(iii) or 11 or in satisfaction of any Failure Payments
under Section 10 ; provided, however, in no event shall the
Shelf Registration Statement(s) be required to register in the
aggregate more than [***] shares of Common Stock. To
the extent the Shelf Registration Statement provided for under this
paragraph is effective, at any time that shares of Common Stock are
issuable to the Holder upon a redemption of the Warrant under
Sections 5(c)(iii) or 11 or in satisfaction of any Failure
Payments under Section 10, such shares delivered to the Holder
shall be registered pursuant to such Shelf Registration Statement.
Notwithstanding anything to the contrary herein (i) the
Company may delay or suspend the effectiveness of a Shelf
Registration Statement or the use of any prospectus forming a part
of a Shelf Registration Statement due to the non-disclosure of
material, non-public information concerning Company the disclosure
of which at the time is not in its best interest, in the good
faith
[***] Certain confidential information contained
in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to
Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
7
opinion of the Company; provided that no such
periods shall individually exceed 90 days or in the aggregate
exceed 90 days during any 12-month period and (ii) a delay in
the effectiveness of a Shelf Registration Statement caused solely
by the filing of a request for confidential treatment shall not be
deemed an Event of Failure or an Event of Default
herein.
5. Adjustments Upon Certain Events
.
(a) Participation . The Holder, as
the holder of this Warrant, shall be entitled to receive such
dividends paid and distributions of any kind made to the holders of
Common Stock of the Company to the same extent as if the Holder had
Exercised this Warrant into Common Stock (without regard to any
limitations on exercise herein or elsewhere and without regard to
whether or not a sufficient number of shares are authorized and
reserved to effect any such exercise and issuance) and had held
such shares of Common Stock on the record date for such dividends
and distributions. Payments under the preceding sentence shall be
made concurrently with the dividend or distribution to the holders
of Common Stock.
(b) Recapitalization or
Reclassification. If the Company shall at any time effect a
recapitalization, reclassification or other similar transaction of
such character that the shares of Common Stock shall be changed
into or become exchangeable for a larger or smaller number of
shares, then upon the effective date thereof, the number of shares
of Common Stock which Holder shall be entitled to purchase upon
Exercise of this Warrant shall be increased or decreased, as the
case may be, in direct proportion to the increase or decrease in
the number of shares of Common Stock by reason of such
recapitalization, reclassification or similar transaction, and the
Exercise Price shall be, in the case of an increase in the number
of shares, proportionally decreased and, in the case of decrease in
the number of shares, proportionally increased. The Company shall
give Holder the same notice it provides to holders of Common Stock
of any transaction described in this Section 5(b).
(c) Rights Upon Major Transaction .
Certain capitalized terms used in this Section and not defined
elsewhere have the meanings given to them below.
(i) Major Transaction.
[***] then the Holder shall have the right to require the
Company to redeem all or a portion of the Holder’s
outstanding Warrants [***] in accordance with
Section 5(c)(iii) below. In addition, in the event
of a Qualified Change of Control Transaction, to the extent the
Holder shall not have exercised its right to require the Company to
redeem the Holder’s Warrants within the applicable time
periods set forth herein, then the Major Transaction shall be
treated as an Assumption (as defined below) in accordance with
Section 5(c)(ii). Notwithstanding anything herein to the
contrary, the Holder shall have the right to waive its rights under
this Section 5(c) with respect to all or any portion of
any Major Transaction in which event none of the provisions of this
Section 5(c)(i) shall apply.
[***]
Each of the following events shall
constitute a “ Major Transaction ”:
(A) a consolidation, merger,
exchange of shares, recapitalization, reorganization, business
combination or other similar event, (1) following which the
holders of Common Stock immediately preceding such consolidation,
merger, exchange, recapitalization, reorganization, combination or
event either (a) no longer hold a majority of the shares of
Common Stock or (b) no longer have the ability to elect a
majority of the board of directors of the Company or (2) as a
result of which shares of Common Stock shall be changed into (or
the shares of Common Stock become entitled to receive) the same or
a different number of shares of the same or another class or
classes of stock or securities of the Company or another entity
(collectively, a “ Change of Control Transaction
”);
(B) the sale or transfer in one
transaction or in a series of related transactions (i) of all
or
[***] Certain confidential information contained
in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to
Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
8
substantially all of the assets of the
Company, (ii) of assets for a purchase price equal
to more than [***] , or (iii) of assets that
represent 50% or more of the assets [***] ;
(C) a purchase, tender or
exchange offer made to the holders of outstanding shares of Common
Stock, such that following such purchase, tender or exchange offer
a Change of Control Transaction shall have occurred and is
consummated;
(D) the liquidation,
bankruptcy, insolvency, dissolution or winding-up (or the
occurrence of any analogous proceeding) of the Company;
or
(E) the shares of Common Stock
cease to be listed, traded or publicly quoted on NASDAQ and are not
promptly re-listed or requoted on either the New York Stock
Exchange, the NYSE Afternext U.S., or the NASDAQ Global Select
Market; or the NASDAQ Capital Market; or
(F) the Common Stock ceases to
be registered under Section 12 of the Exchange Act.
For purposes hereof, the following
terms have the definitions set forth below:
A “ Cash-Out Major
Transaction ” means a Major Transaction in which the
consideration payable to holders of Common Stock in connection with
the Major Transaction consists solely of cash.
An “ Eligible Market
” means the over the counter Bulletin Board, the New York
Stock Exchange, Inc., the NYSE Arca, the NASDAQ Capital
Market, the NASDAQ Global Market, the NASDAQ Global Select Market
or the American Stock Exchange.
A “ Mixed Major
Transaction ” means a Major Transaction in which the
consideration payable to the shareholders of the Company consists
partially of cash and partially of securities of a Successor
Entity. If the Successor Entity is a Publicly Traded
Successor Entity, the percentage of consideration represented by
securities of such Successor Entity shall be equal to the
percentage that the value of the aggregate anticipated number of
shares of the Publicly Traded Successor Entity to be issued to
holders of Common Stock of the Company represents in comparison to
the aggregate value of all consideration, including cash
consideration, in such Mixed Major Transaction, as such values are
set forth in any definitive agreement for the Mixed Major
Transaction that has been executed at the time of the first public
announcement of the Major Transaction or, if no such value is
determinable from such definitive agreement, based on the closing
market price for shares of the Publicly Traded Successor Entity on
its principal securities exchange on the Trading Day preceding the
first public announcement of the Mixed Major Transaction. If the
Successor Entity is a Private Successor Entity, the percentage of
consideration represented by securities of such Successor Entity
shall be determined in good-faith by the Company’s Board of
Directors
[***]
A “ Parent Entity
” of a Person means an entity that, directly or indirectly,
controls the applicable Person and whose common stock or equivalent
equity security is quoted or listed on an Eligible Market, or, if
there is more than one such Person or Parent Entity, the Person or
Parent Entity with the largest public market capitalization as of
the date of consummation of a Major Transaction.
A “ Person ”
means a limited liability company, a partnership, a joint venture,
a corporation or a trust.
A “ Publicly Traded
Successor Entity ” means a Successor Entity that is a
publicly traded corporation whose common stock is quoted on or
listed for trading on an Eligible Market (as defined
below).
[***] Certain confidential information contained
in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to
Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
9
[***]
“ Redemption Shares
” means shares of Common Stock of the Company that may be
issuable from time to time pursuant to Section 5(c)(iii), 10
and/or 11 hereof and that are registered for resale under the
Securities Act pursuant to an effective registration statement
filed by the Company as contemplated by Section 4(c) or,
if such a registration statement is not then effective, shares of
Common Stock of the Company that are not so registered.
A “ Successor Entity
” shall be a Person as defined in
Section 5(c)(ii) below.
(ii) Assumption. The Company
shall not enter into or be party to a Major Transaction that is to
be treated as an Assumption pursuant to
Section 5(c)(i) above unless any Person purchasing the
Company’s assets or Common Stock, or any successor entity
resulting from such Major Transaction, or if the Warrant is to be
exercisable for shares of its Parent Entity (as defined above), its
Parent Entity (in each case, a “ Successor Entity
”), shall have assumed in writing all of the obligations of
the Company under this Warrant and the Registration Rights
Agreement in accordance with the provisions of this subsection
(ii) pursuant to written agreements in form and substance
reasonably satisfactory to the Holder and approved by the Holder
prior to such Major Transaction (not to be unreasonably withheld or
delayed), including agreements to deliver to each holder of
Warrants in exchange for such Warrants a security of the Successor
Entity evidenced by a written instrument substantially similar in
form and substance to the Warrants, including, without limitation,
an instrument representing the appropriate number of shares of the
Successor Entity, having similar exercise rights as the Warrants
(inclu